Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9NPJ3

UPID:
ACO13_HUMAN

ALTERNATIVE NAMES:
Hotdog-fold thioesterase superfamily member 2; Palmitoyl-CoA hydrolase; Thioesterase superfamily member 2

ALTERNATIVE UPACC:
Q9NPJ3; F5H2L4; O95549

BACKGROUND:
The enzyme Acyl-coenzyme A thioesterase 13, recognized as Thioesterase superfamily member 2, plays a crucial role in lipid metabolism by breaking down acyl-CoAs into free fatty acids and coenzyme A. Its activity is essential for maintaining the balance of fatty acids within cells and is involved in the hydrolysis of various acyl-CoA molecules, including medium and long-chain fatty acids. The enzyme's potential role in adaptive thermogenesis highlights its importance in energy homeostasis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Acyl-coenzyme A thioesterase 13 offers a promising avenue for developing novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.